TY - JOUR
T1 - Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients
T2 - A Systematic Review
AU - Farooqui, Arafat Ali
AU - Ashraf, Aqsa
AU - Farooq, Talha Bin
AU - Anjum, Ahmad
AU - Rehman, Saif ur
AU - Akbar, Arshia
AU - Kanate, Abraham
AU - Dean, Robert
AU - Ahmed, Malik Qistas
AU - Tariq, Muhammad Junaid
AU - Nabeel, Shaha
AU - Faisal, Muhammad Salman
AU - Anwer, Faiz
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/7
Y1 - 2020/7
N2 - Chronic lymphocytic leukemia (CLL) typically affects older patients; administration of traditional cytotoxic therapies in old patients has very modest benefit with no survival improvement. With better understanding of CLL biology, trends are shifting towards the use of targeted therapies. The objective of this article is to review the safety and efficacy of various novel agents that specifically target the dysregulated pathways, with particular attention to elderly patients. Agents like B-cell receptor (BCR) inhibitors (Bruton's tyrosine kinase inhibitors [ibrutinib]), phosphatidylinositol 3-kinase inhibitors (idelalisib), spleen tyrosine kinase inhibitors (entospletinib), Bcl-2 inhibitors (venetoclax), immunomodulators (lenalidomide), and monoclonal antibodies (obinutuzumab, ofatumumab) have shown activity in CLL with a very favorable toxicity profile. Newer agents have improved clinical outcomes, and have tolerable toxicity profiles in elderly patients, resulting in the treatment with individualized therapy approach for CLL.
AB - Chronic lymphocytic leukemia (CLL) typically affects older patients; administration of traditional cytotoxic therapies in old patients has very modest benefit with no survival improvement. With better understanding of CLL biology, trends are shifting towards the use of targeted therapies. The objective of this article is to review the safety and efficacy of various novel agents that specifically target the dysregulated pathways, with particular attention to elderly patients. Agents like B-cell receptor (BCR) inhibitors (Bruton's tyrosine kinase inhibitors [ibrutinib]), phosphatidylinositol 3-kinase inhibitors (idelalisib), spleen tyrosine kinase inhibitors (entospletinib), Bcl-2 inhibitors (venetoclax), immunomodulators (lenalidomide), and monoclonal antibodies (obinutuzumab, ofatumumab) have shown activity in CLL with a very favorable toxicity profile. Newer agents have improved clinical outcomes, and have tolerable toxicity profiles in elderly patients, resulting in the treatment with individualized therapy approach for CLL.
KW - Elderly
KW - Lymphocytic Leukemia-Chronic B Cell
KW - Monoclonal antibodies
KW - Personalized therapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85083045069&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2020.02.013
DO - 10.1016/j.clml.2020.02.013
M3 - Review article
C2 - 32291235
AN - SCOPUS:85083045069
SN - 2152-2650
VL - 20
SP - e414-e426
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 7
ER -